ArticleCancer immunology, immunotherapy : CII2019
Neoadjuvant cisplatin and paclitaxel modulate tumor-infiltrating T cells in patients with cervical cancer.
Article in Cancer immunology, immunotherapy : CII, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Research progress and perspectives on the application of tyramide signal amplification-based multiplex immunohistochemistry/immunofluorescence: a bibliometrics analysis.Frontiers in oncology · 2024Pooled it
- CD155 links tumor immunotype to epithelial-directed precision therapy beyond checkpoint inhibition in cervical cancer.Journal for immunotherapy of cancer · 2026Article
- Review
- Therapeutic connections between pyroptosis and paclitaxel in anti-tumor effects: an updated review.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- Preoperative MRI-based radiomics analysis of intra- and peritumoral regions for predicting CD3 expression in early cervical cancer.Scientific reports · 2025Article
- Neoadjuvant therapy-induced immune dynamics and myeloid-associated resistance in advanced head and neck cancer.NPJ precision oncology · 2025Article
- Patients with Cervical Cancer with and without HIV Infection Have Unique T-cell Activation Profiles despite Similar Survival Outcomes after Chemoradiation.Cancer research communications · 2025Article
- Transcriptome and microbiome-immune changes across preinvasive and invasive anal cancer lesions.JCI insight · 2024Article
- SETD8, a frequently mutated gene in cervical cancer, enhances cisplatin sensitivity by impairing DNA repair.Cell & bioscience · 2023Article
- Article
- Systematic approach to identify therapeutic targets and functional pathways for the cervical cancer.Journal, genetic engineering & biotechnology · 2023Article
- CNN stability training improves robustness to scanner and IHC-based image variability for epithelium segmentation in cervical histology.Frontiers in medicine · 2023Article
- Effect of neoadjuvant chemotherapy on the immune microenvironment of gynaecological tumours.Annals of medicine · 2023Review
- Advances in immunotherapy for cervical cancer.Therapeutic advances in medical oncology · 2023Review
- Downregulation of Circ-CEP128 Enhances the Paclitaxel Sensitivity of Cervical Cancer Through Regulating miR-432-5p/MCL1.Biochemical genetics · 2022Article
- Article
- The immune modifying effects of chemotherapy and advances in chemo-immunotherapy.Pharmacology & therapeutics · 2022Review
- A Review of the Effects of Cervical Cancer Standard Treatment on Immune Parameters in Peripheral Blood, Tumor Draining Lymph Nodes, and Local Tumor Microenvironment.Journal of clinical medicine · 2022Review
- Immunotherapy for Cervical Cancer: Are We Ready for Prime Time?International journal of molecular sciences · 2022Review
- Combinatorial regimens of chemotherapeutic agents: A new perspective on raising the heat of the tumor immune microenvironment.Frontiers in pharmacology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Resistance to chemotherapy is widely recognized as one of the major factors limiting therapeutic efficacy and influences clinical outcomes in patients with cancer. Many studies on various tumor types have focused on combining standard-of-care chemotherapy with immunotherapy. However, for cervical cancer, the role of neoadjuvant chemotherapy (NACT) on the local immune microenvironment is largely unexplored. We performed a pilot study on 13 primary cervical tumor samples, before and after NACT, to phenotype and enumerate tumor-infiltrating T-cell subpopulations using multiplex immunohistochemistry (CD3, CD8, FoxP3, Ki67, and Tbet) and automated co-expression analysis software. A significant decrease in proliferating (Ki67
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.